Form 4: Nuvalent's Chief Development Officer, Darlene Noci, Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Darlene Noci, Chief Development Officer of Nuvalent, Inc., exercised stock options and sold shares of Class A Common Stock on October 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On October 1, 2024, Darlene Noci, the Chief Development Officer of Nuvalent, Inc., engaged in transactions involving the company's Class A Common Stock.
- Noci exercised a stock option to acquire 5,000 shares at a price of $18.93 per share.
- Simultaneously, Noci sold a total of 5,000 shares in multiple transactions at weighted average prices ranging from $99.93 to $104.69.
- These transactions were executed under a pre-existing Rule 10b5-1 trading plan adopted on December 21, 2023.
- Following these transactions, Noci directly owns 33,300 shares of Class A Common Stock and holds options for 35,800 shares.
Sentiment
Score: 5
Explanation: This is a routine filing related to insider transactions under a pre-arranged trading plan. It doesn't necessarily indicate positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment of interests between management and shareholders. The use of a 10b5-1 trading plan indicates that these transactions were pre-planned and not based on any inside information at the time of the trades.
Comparison to Industry Standards
- Insider transactions are a common occurrence in publicly traded companies.
- The use of Rule 10b5-1 trading plans is a standard practice to avoid accusations of insider trading.
- Comparable companies such as Relay Therapeutics, Black Diamond Therapeutics, and Blueprint Medicines also have executives who regularly file Form 4s for stock transactions.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the trades mitigates concerns about insider information.
Key Dates
| Date | Description |
|---|---|
| 2023-12-21 | Date of adoption of Rule 10b5-1 trading plan |
| 2024-01-04 | Initial vesting date for stock options |
| 2024-10-01 | Date of stock option exercise and stock sales |
| 2032-01-04 | Expiration date of stock options |
| 2024-10-02 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.